Overview

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UCB Pharma
Treatments:
N 0437
Rotigotine
Criteria
Inclusion Criteria:

- Subjects who have completed treatment in one of the SP824 (NCT00242008), SP825
(NCT00243971), or SP826 (NCT00243945) trials

Exclusion Criteria:

- Subjects who had an ongoing serious adverse event from the previous OLE trial that was
assessed as related to study medication